OncoArendi raises 4.5 mln USD (18 million PLN) in an extension of Series A financing round

As a part of the extension of Series A financing round, OncoArendi Therapeutics S.A. has raised 4.5 mln USD (18 million PLN) for continued development of its small molecule drug discovery programs for treatment of cancer and respiratory diseases. These funds, significantly complemented by the grant funding received from the Natioal Center for Research and Development (NCBR) as well as the European Commission (Horizon2020) will enable the company to progress its four key assets up to Phase II clinical trials for the following indications: cancer (lung, colon, gliaoblastoma multiforme or mylenoma), asthma, idiopathic pulmonary fibrosis or chronic obstructive pulmonary disease. The recent equity financing round sparked high interest from institutional and individual private investors.